References
1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1):S1–S266.
2. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kid Dis 2003;41:1–12.
3. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489–495.
4. St. Peter WL, Schoolwerth AC, McGowan T, et al. Chronic Kidney disease: issues and establishing programs and clinics for improved patient outcomes. Am J Kidney Dis 2003;41:903–924.
5. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 2003;14:S65–S70.
6. National Kidney Foundation. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kid Dis. 2004;43(1 Suppl):S1–S290.
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
8. Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington county, Maryland. J Am Soc Nephrol 2003;14:2934–2941.
9. Hsu C, McCulloch CE, Darbinian J, et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923–928.
10. Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–426.
11. Wali RK, Henrich WL. Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin 2005;23:343–362.
12. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know, what do we need to learn, where do we go from here? National Kidney Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853–906.
13. Shulman NH, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1998;13(5 Suppl):I80–I93.
14. Henry RMA, Kostense PJ, Bos Griet, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the HOORN study. Kidney Int 2002;62:1402–1407.
15. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307–1315.
16. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347–354.
17. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003;42:617–622.
18. deZeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006;17:2100–2105.
19. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005;112:969–975.
20. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987;294:1443–1447.
21. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134–1146.
22. UK Prospective Diabetes Study Group. UKPDS 38: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998;317:703–713.
23. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309–2320.
24. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
25. Bakris GL, Weir MR, Shnifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555–1565.
26. Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992–999.
27. Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician 2004;70:1921–1928.
28. National Kidney Foundation. K/DOQI Clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kid Dis 2003;41(13 Suppl):S1–S290.
29. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass increase in early renal disease: impact in decline in hemoglobin. Am J Kidney Dis 1999;34:125–134.
30. Silverberg D, Wexler D. Anemia, the fifth cardiovascular risk factor. Transfus Med Hemother 2004;31:175–179.
31. McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 2005;6(suppl 3):S4–S12.
32. Stevens LA, Fares G, Fleming J, et al. Low rates of testing and diagnostic code usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol 2005;16:2439–2448.
33. Hebert CJ. Preventing kidney failure: primary care physicians must intervene earlier. Cleve Clin J Med 2003;70:337–344.
35. Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines for chronic kidney disease in adults: part II, glomerular filtration rate, proteinuria and other markers. Am Fam Physician 2004;70:1091–1097.
36. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
37. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
39. Bakris GL. Implications of albuminuria on kidney disease progression. J Clin Hypertens (Greenwich) 2004;6(suppl 3):18–22.
40. Basile J. Chronic kidney disease: it’s time to recognize its presence in our patients with hypertension. J Clin Hypertens 2004;6:548–552.